Pharmaceutical News and Articles

Ozempic or Saxenda for Weight Loss: Which Works Best?

Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appet

Boar's Head Will Close Virginia Plant Linked to Listeria-Tainted Deli Meats

were all observed by inspectors at the Jarratt plant in June.In its Friday statement, Boar s Head said that, in response to the inspection records and noncompli

Ozempic, Mounjaro Help People With Type 1 Diabetes Control Blood Sugar, Lose Weight

something that won t help type 1 diabetics, who have lost the ability to produce any insulin.However, the drugs also slow down digestion of food and reduce the

A-Fib Risk Drops Soon After Quitting Smoking

Smokers who make the decision to quit will see almost immediate health benefits, including a quick drop in their risk for atrial fibrillation, new research show

Source of Missouri Bird Flu Case Still Unknown, Could Be a 'One-Off': CDC

In a case that continues to confound scientists, U.S. health officials said Thursday that they still don t know how a Missouri patient caught the bird flu and t

Over 5 Million Americans Could Benefit If Psilocybin Approved for Depression: Study

it might help ease tough-to-treat depression.The drug is now under consideration by the FDA as a possible new treatment for depression.Just how many Americans m

1 in 3 Store-Bought Cinnamon Samples Tested Have Elevated Lead Levels

One third of cinnamon products tested by Consumer Reports contained elevated levels of lead, the watchdog agency warned Thursday.The finding follows concerns ab

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat (NBI-10

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis